The issue is they are spending lots of $$ on direct sales force but not getting sales traction. I agree, hard to know what to do. Think i'll put it down as another investor lesson.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling